Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Inhibits the SARS-CoV-2 main protease (3CLpro/Mpro), preventing cleavage of viral polyproteins required for replication and assembly of functional viral proteins.
Indications / reported uses
Post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older under the EU-authorised ZOKOVEA indication (EU marketing authorisation issued 18 September 2026). Do not extrapolate this indication to treatment of established COVID-19 or other jurisdictions without a corresponding authorisation.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Ensitrelvir PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ensitrelvir Permitted Daily Exposure (PDE) report (the Ensitrelvir PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ensitrelvir Occupational Exposure Limit (OEL) report (the Ensitrelvir OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.